All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-7531
Requests that the FDA declare that Buspirone HCl Oral Solution, 2.5 mg/mL, is suitable for submission as an ANDA.
Documents
7
Comments
0
Key Dates
Comment Period OpensJul 7, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Hyman, Phelps & McNamara, P.C.
Requests that the FDA declare that Buspirone HCl
Oral Solution, 2.5 mg/mL, is suitable for
submission as an ANDA
OPEN
Data from Regulations.gov